Skip to main content

Advertisement

Table 3 In clinical trials/Novel Targets

From: Potential new targets for drug development in severe asthma

Specific target Drug Biomarkers Outcomes Potential Adverse Events References
CRTH2 OC000459 (Phase 2) None Improved FEV1 and quality of life scores Cardiovascular and cerebrovascular events; helminthic and viral infections Barnes 2012 [31]
Pettipher 2014 [32]
  BI 671800 (Phase 2) None Mixed results for FEV1
improvement
Mixed results for asthma control scores
Cardiovascular and cerebrovascular events; helminthic and viral infections  
  QAW039/Fevipiprant (Phase 3) ↑Sputum eosinophils (≥2% for Gonem et al.) Decreased sputum eosinophils
Mixed results for FEV1 improvement
Mixed results for asthma control scores
Cardiovascular and cerebrovascular events; helminthic and viral infections Gonem 2016 [39]
Erpenbeck 2016 [37]
Bateman 2017 [38]
  ARRY-602 (Phase 2) ↑Th2 associated biomarkers Improved FEV1, asthma control and quality of life score Cardiovascular and cerebrovascular events; helminthic and viral infections Wenzel 2014
TSLP AMG 157/Tezepelumab (Phase 2) None Reduced early and late response (FEV1
decrease) to allergen challenge
Decreased exacerbations
Improved FEV1
Decreased blood eosinophils, FeNO, and total IgE
Cardiovascular and cerebrovascular events; skin infections; Guillain-Barre Gauvreau 2014 [48]
Corren 2017 [49]
CXCR2/IL-8 SCH527123/Navarixin (Phase 2) ↑Sputum neutrophils (>  40%) Decreased sputum neutrophils
Trend towards improved asthma control
Nasopharyngitis; neutropenia Nair 2012 [73]
  AZD5069 (Phase 2) ↑Blood neutrophils (≥ 2.7 × 109/L) No difference in exacerbations Nasopharyngitis; neutropenia O’Byrne 2016 [74]
IL-33 REGN3500 (Phase 1)
ANB020 (Phase 2)
Results pending   Cardiovascular and cerebrovascular events; helminthic and viral infections  
IL-25   No biologics in human trials yet   Cardiovascular and cerebrovascular events; helminthic and viral infections  
IL-17A CCJM112 (Phase 2) Low IgE and Blood Eosinophils